Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rockwell MedicalSTU:RWM 48 Debt-to-Equity is 0.40 as of Jun. 2026, which is 35% below its 10-year median of 0.62. GuruFocus rates STU:RWM with a GF Score™ of 48/100 and a GF Value™ of €5.23 (Fairly Valued). The stock has 2 warning signs investors should review. Among 810 Drug Manufacturers companies, Rockwell Medical ranks worse than 61.48% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Rockwell Medical's Debt-to-Equity or its related term are showing as below:
STU:RWM'
s Debt-to-Equity Range Over the Past 10 Years
Min: -5.37 Med: 0.62 Max: 11.4
Current: 0.4
During the past 13 years, the highest Debt-to-Equity Ratio of Rockwell Medical was 11.40. The lowest was -5.37. And the median was 0.62.
STU:RWM's Debt-to-Equity is ranked worse than 61.48% of 810
companies
in the Drug Manufacturers industry
Industry Median: 0.275
vs STU:RWM: 0.40
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Rockwell Medical Debt-to-Equity Related Terms
Rockwell Medical Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Rockwell Medical's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:RWM vs BTAI, MRMD, TXMD: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rockwell Medical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rockwell Medical Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rockwell Medical's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Rockwell Medical's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rockwell Medical (STU:RWM) has a Debt-to-Equity of 0.40 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Rockwell Medical and its competitors. This is 35% below median its historical median of 0.62. According to the industry distribution chart, Rockwell Medical ranks #498 out of 810 companies in the Drug Manufacturers industry, placing it in the top 61.5%.
Is Rockwell Medical's Debt-to-Equity too high?
Rockwell Medical's current Debt-to-Equity of 0.40 is 35% below median its 10-year median of 0.62. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Rockwell Medical's value of 0.40 is 45.5% above this industry median. Based on the distribution chart, Rockwell Medical ranks #498 out of 810 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Rockwell Medical has a GF Score™ of 48/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Rockwell Medical's Debt-to-Equity compare to BTAI and MRMD?
According to the Drug Manufacturers industry distribution chart, Rockwell Medical ranks #498 out of 810 companies for Debt-to-Equity. This places Rockwell Medical in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Rockwell Medical's value of 0.40 is 45.5% above this benchmark. While the company's 10-year median is 0.62 vs. the industry median of 0.28, Rockwell Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rockwell Medical's current Debt-to-Equity of 0.40 is 45.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Rockwell Medical and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rockwell Medical's current Debt-to-Equity is 0.40, which is 35% below median its own 10-year median of 0.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rockwell Medical stock overvalued right now?
Based on GuruFocus' analysis, Rockwell Medical (STU:RWM) is currently considered Fairly Valued. The stock's GF Value™ is €5.23, compared to a current price of €4.80 — trading 8.2% below its estimated fair value. The current Debt-to-Equity is 0.40, which is 35% below median its 10-year median of 0.62 and 45.5% above the Drug Manufacturers industry median of 0.28. Rockwell Medical's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Rockwell Medical (STU:RWM), the current Debt-to-Equity is 0.40 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rockwell Medical (STU:RWM) Overvalued in 2026?
Based on GuruFocus' analysis, Rockwell Medical stock appears to be undervalued.
The current stock price of €4.80 is trading 8.2% below its estimated GF Value™ of €5.23.
GuruFocus considers Rockwell Medical to be Fairly Valued.
Key valuation signals for STU:RWM:
Debt-to-Equity: 0.40 (35% below median its 10-year median of 0.62)
GF Value™: €5.23 vs. price of €4.80 (8.2% below fair value)
Industry Position: 45.5% above the Drug Manufacturers median (#498 of 810)
No single metric tells the full story. See the STU:RWM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
48GF Score
Get the complete analysis for STU:RWM
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:RWM has been successfully added to your 
